	Prof. Bikash Medhi
	Designation : Professor
	Department : PHARMACOLOGY
	medhi.bikash@pgimer.edu.in

:: Contact Details

Phone No.

9914207510

Ext No.

5250

:: Educational Qualification

Graduation

MBBS from Assam Medical College Dibrugarh in year 1992

Post Graduation

MD from AIIMS New Delhi in year 1997

:: Area of Interest

Area Of Interest

1. Experimental Pharmacology

2. Clinical Pharmacology

3. Molecular Pharmacology
4. Clinical Research

5. Regulatory Pharmacology

6. Development of Nanoformulations

7. Pharmacogenomics

8. Pharmacovigilance and Materiovigilance

9. Regulatory Affairs

10. New Drug Development

:: Research & Projects

Extramural Projects

EXTRAMURAL GRANTS

Sr. No.	Project title	Funding agency	Starting Date	Completion date	Status
1.		Minstry of Ayush	Dec 2025	Dec 2027	Ongoing
2.		ICMR	Feb 2024	Feb 2027	Ongoing
3.		ICMR	Feb 2024	Feb 2027	Ongoing
4.		ICMR	April 2022	April 2025	Ongoing
5.	To study the brain and gut axis of cognition-behavioral assessment in celiac disease patients in the stratified Indian population: study in northern tertiary care center 58/20/2020/PHA/BMS	ICMR	08-10-2021	07-10-2023	Completed
6.		SERB	02-03-2022	01-03-2025	Ongoing
7.	The efficacy and safety of n-acetylcysteine in autism spectrum disorder (ASD): a systematic review and meta-analysis of randomized clinical trials 5/7/1702/CH/ADHOC/RBMCH2020	ICMR	01-12-2020	30-06-2022	Completed
8.	To create an awareness regarding the rational use of medicines and current drug resistant profile (antibiotic resistance) among school students CO/B/FP/G07/2019	DST	25-02-2020	24-02-2023	Completed
9.	Adverse drug reactions and gene polymorphism: linking the evidence -based research in drug treatment and onset of adverse drug reaction82/16/2012/PHGEN(TF)/BMS	ICMR	31-03-2017	30-03-2020	Completed
10.	Clinical metabolomic and pharmacogenomic predictors of anti-tubercular therapy (ATT) induced hepatitis in patients with tubercular meningitis 2019-0927-CMB/ ADHOC/ BMS	ICMR	05-09-2019	04-09-2022	Completed
11.	Rational use of drugs 65/11/2018/RUD/BMS/PGI	ICMR	01-07-2019	30-06-2022	Completed
12.	Elucidation of effect of cystamine and thymulin alone and in combination in experimental model of celiac disease in mice: an exploratory study 58/1/2018-BMS	ICMR	01-01-2019	31-12-2021	Completed
13.	To evaluate the role of calorie restriction along with a modulator on circadian rhythm regulation and their combined effect on glioma suppression: in vitro and in vivo studies 5/9/1211/2019-NUT	ICMR	01-12-2019	31-05-2022	Completed
14.	Drug development unit and training center for neurological disorders: a capacity building program VI-D&P/617/2018-19/TDT (G)	DST	07-07-2019	06-07-2022	Completed
15.	Role of metformin in modulating neuro-immunoinflammation in experimental model of status epilepticus BT/PR13137/MED/122/74/2017	DBT	10-05-2017	04-02-2021	Completed
16.	Effect of risperidone and withania somnifera treatment alone and in combination on behavioral and molecular parameters in a modified valproic acid induced model of autistic spectrum disorders (asd) and experimentally induced epilepsy in rats BT/PR7555/PBD/17/845/2013	DBT	13-02-2014	12-02-2017	Completed
17.	Nephroprotective therapeutic validation of ethnomedicinal plants of ne India against cisplatin induced chemotherapeutic toxicity BT/335/NE/TBP/2012)	DBT	16-01-2014	15-01-2017	Completed
18.	To establish the diagnostic criteria for the celiac disease patient with the higher titers of h-ttg/dgp SB/SO/HS/0189/2013	DST	03-06-2015	02-06-2018	Completed

INDEPENDENT FELLOWSHIP PROJECTS

1	Identification And Evaluation Of Novel Transglutaminase 2 And Interleukin-15 Inhibitors In Celiac Disease: An In Silico, In Vitro And In Vivo Study 3/1/2/242/2021-NUT	ICMR RA Ashutosh	01-06-2022	31-05-2025	Completed
2	Study to screen and optimize the new chemical entities targeting glutamate transporters using in-silico studies and it evaluations of pharmacological activities in cell line and valproic acid induced experimental animal model 45/30/2020/PHA/BMS	ICMR SRF ANUPAM	26-06-2021	25-06-2023	Completed
3	Identification and biological evaluation of novel cathepsin s inhibitors as potent immunomodulators in celiac disease3/1/2 (18)/CD/2021-NCD-II	ICMR RA RAHUL	18-06-2021	17-06-2024	Completed
5	Targeted Drug Delivery of Everolium using Phopholipid/ Lipid Polymer Based Nano Formulation for Treatment Of Pancreatic Neuroendocrine Tumors: Potential For Translational Research 5/3/8/73/ITR-F/2020-ITR	ICMR DR GURJEET	03-08-2020	02-08-2023	Completed
6	To study the neuroprotective effect of perk inhibitor, GSK- 2606414 in middle cerebral artery occlusion induced model of stroke in rats R. 12014/18/2018-HR	DHR NEHA	01-11-2018	30-04-2022	Completed
7	A prospective cohort study to evaluate predictors of persistent thrombocytopenia in patients suffering from dengue fever12014/07/2018-HR	DHR DR PHULEN	15-05-2018	14-05-2021	Completed
8	To elucidate the role of 17 alpha estradiol (neuroserm) on parkinsonism in translational and surgical animal model of menopause45/31/2019/PHA/BMS	ICMR DR SEEMA	01-07-2019	30-06-2022	Completed
9	To investigate the neuroprotective effect of granulocyte colony stimulating factor (gcsf) and plant herb in experimental model of autism spectrum disorder (asd) in rat 45/47/2018/PHA/BMS-OL	ICMR ABHISHEK	07-12-2018	25-10-2021	Completed
10	To study the effects of a selective akt inhibitor 10- debc hydrochloride in dmh induced experimental model of colorectal cancer in rats3/1/3/JRF-2017/HRD-LS/50738/15	ICMR SANIYA	22-08-2017	21-08-2022	Completed
11	Effect of interplay between mir-2909 and anti-psychotic drugs on cancer cell epigenomics 5/3/8/12/ITR-F/2019-ITR	ICMR DR DEEPTI	13-08-2019	12-08-2022	Completed
12	Understanding the potential mechanisms of third generation antiepileptic drugs i.e. brivaracetam and eslicarbazepine against cognitive impairment induced by kindling model of epilepsy in rats: a proof-of-concept study PDF/2016/002665	ICMR DR RUPA	15-05-2017	14-05-2019	Completed
13	Pharmacological investigations to explore the role of pi3k/ akt pathway in type-3 diabetes PDF/2016/003741	ICMR DR SEEMA	21-06-2017	20-06-2019	Completed
14	Study of fingolimod, nitric oxide inhibitor and p-gp inhibitor in reducing p-glycoprotein activity: functional implication for pharmacoresistance in epilepsy3/1/3/JRF-2014/HRD-49	ICMR NITIKA	01-01-2015	31-12-2019	Completed
15	Development of ophthalmic formulations of acetazolamide and memantine using novel drug delivery techniques for the treatment of glaucoma(45/8/2012-PHA/BMS)	ICMR BALDEEP	01-08-2012	31-07-2017	Completed
16	Mechanistic exploration of role of metformin in neurodegeneration3/1/3/JRF-2014/HRD	ICMR HARISH	01-10-2014	30-09-2019	Completed
17	Evaluation Of Alternative Non- Dietary Therapeutic Approach For Celiac Disease 3/1/3/JRF-2012/HRD	ICMR RAHUL	01-10-2012	30-09-2017	Completed
18	In Vitro And In Vivo Study Of Antimalarial Compounds	ICMR SHWETA	2012	2017	Completed

INDUSTRY FELLOWSHIP PROJECTS

Arjuna

Ongoing

Nita Life Science

Ongoing

A multicentric, open label, non-comparative, prospective evaluation of

misuse potential (if any), of Proxyvon (combination of Propoxyphene napsylate

and Acetaminophen) in Indian patients with mild to moderate painâ.

Wockhardt

Completed

S. No.	Project Title	Sanction date/Start date/ Proposed Completion Date	Sponsoring agency	Highlighting of Progress (in 100 Words)
1.	Development of functionalized nano-formulation of chalcones for enhanced anti-malarial efficacy 45/25/2020-NANO BMS	14-Jan-2021 to 27-Dec-2024	ICMR- RA Shweta Sinha	Completed
2.	Combined effects of G-CSF and dizocilpine (MK-801) on acute phase changes induced by partial global cerebral ischemia in mice (58/18/2008-BMS)	15.09.2010 to 15.09.2013	ICMR	Completed
3.	Study to evaluate correlation of different type of peripheral inflammation and epilepsy and role of cytokines in inflammation induced in experimental model in rats (58/26/2010-BMS)	01.01.2012 to 31.12.2014	ICMR	Completed
4.	Effect of Metformin on Alzheimerâs Disease in rats (54/18/2008-BMS)	01.11.2012 to 31.10.2015	ICMR	Completed
5.	Comparative Evaluation of Thalidomiode, Sulfasalazine with Nanotechnology Based Drug Delivery in Experimentally Induced Inflammatory Bowel Disease in Rats (45/24/2011/NAN-BMS)	01.06.2012 to 30.05.2016	ICMR	Completed
6.	Effect of Risperidone and Withaniasomnifera treatment alone and in combination on behavioral and molecular parameters in a modified valproic acid induced model of autistic spectrum disorders (ASD) & experimentally induced epilepsy in rats BT/PR7555/PBD/17/845/2013	27.12.2013 to 27.12.2016	DBT	Completed
7.	Evaluation of the potential of probiotics for the prevention and treatment of intestinal and vaginal infectionâ, (BT/PR-14969/FNS/20/506/2010)	05.07.2011 to 05.07.2014	DBT	Completed
8.	To establish the diagnostic criteria for the celiac disease patients with the higher titers of h-tTG/DGP (SR/SO/HS/189/2013)	22.05.2015 to 22.05.2018	DST	Completed
9.	ICMR project on Pharmacogenomics	2014	ICMR	Completed
10.	ICMR thesis funding of Dr. Ramaya Rao: Experimentally induced various inflammatory models and seizure: understanding the role of cytokine in rat.	2007	ICMR	Completed
11.	ICMR thesis funding of Dr. Veeru Prasad: Comparative evaluation of different doses of green tea extract alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats	2008	ICMR	Completed
12.	ICMR thesis funding of Dr. Prashantrana: Comparative evaluation of aceclofenac, diacerein and ricinoleic acid alone and combination in experimentally induced arthritis in rats.	2009	ICMR	Completed
13.	ICMR thesis funding of Dr. ShobanBabu: Comparative Effect of Different Polyphenols of Green Tea Extract with Nanotechnology Based Drug Delivery alone and Combined with Sulfasalazine in TNBS Induced Inflammatory Bowel Disease in Rats.	2012	ICMR	Completed
14.	Evaluation of effects of antimalarial drugs and their nanoformulations in experimentally induced malaria in drug resistant Plasmodium berghei rodent model (ICMR Independent SRF Shweta)	2014	ICMR	Completed

Extramural grant for Different Centers

S.No.	Project Title	Sanction date/Start date/ Proposed Completion Date	Sponsoring agency	Highlighting of Progress in 100 words
1.	Correlation of Biomarkers and advanced imaging techniques with disease severity in patients with dementia (2013-2744), PI: Dr. Manish Modi	(2013-2744)	ICMR	Completed
2.	Development of pharmacogenomic SNP database of two metabolic genes CYP3A4, CYP2C9 and CYP2C19 for predicting adverse drug reactions in epileptic patients receiving Carbamazepine or Phenytoin therapy in North Indian population (2012-0597) PI: Dr. Manish Modi	(2012-0597)	ICMR	Completed
3	Study of pathogenesis of HSV-1induced uveitis in a rabbit animal model and development of a topical microemulsion of vitamin D as a therapeutic regimen submitted by you for financial support to this Department. The Permanent Project Registration Number of this project is: BT/PR10811/MED/29/840/2014: PI Dr Mini P Singh	BT/PR10811/MED/29/840/2014		Completed
4.	DSIR project, Delhi University Characterization of a unique dihydropyrimidinone, ethyl 4-(4'-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate, as an effective antithrombotic agent in a rat experimental model.	2009-2010		Completed

INTRAMURAL GRANTS

1	Evaluation of 3,3'-diindolylmethane and alpha napthaflavone in experimental model of stroke in rats	INTRAMURAL	08-01-2018	31-03-2020	Completed
2	To elucidate the therapeutic potential of g-csf on experimental model of autism spectrum disorder in rats	INTRAMURAL	14-03-2018	31-03-2020	Completed

Research In
Progress

Pharmacovigilence and Materiovigilance

1. Established Pharmacovigilance Centre and Materiovigilance centre:Pharmacovigilance Centre has been established in the Department ofPharmacology, PGIMER, Chandigarh under the aegis of Central Drugs StandardControl Organization, Ministry of Health and family welfare, Govt. of Indiaw.e.f. Oct, 2010. Later PGIMER has been identified by National CoordinatingCentre, Indian Pharmacopoeia Commission as Regional Resource Centre forNorthern Region for Training and Technical Support for North India. Theprime objective of said centre is to collect the adverse drug reaction-reportsfrom different departments of the Institute and also to foster the culture ofreporting of adverse drug reactions amongst health care professionals. Socollected reports of adverse drug reactions are then entered into Vigiflow;a database maintained and owned by Uppsala Monitoring Center, World Health Organization (WHO).AMC,PGIMER has contributed 10,158 Individual Case Safety Reports (ICSRâs)till July, 2015 since its inception. AMC has a score of 0.94 for thecompleteness of ICSRâs as compared to developed countries. The performance ofthe center has been appreciated time to time by the National CoordinatingCentre, IPC, Ghaziabad and UMC-WHO.

Yearwise distribution of the number of ICSRâs reported by AMC, PGIMER,Chandigarh to NCC-IPC and UMC-WHOis as below:

Furthermore,the centre is also committed to explore its scope to the other hospitals in theneighboring states also.More than 40 awareness seminars have been conducted inNorth Indian states. Being a Regional Resource Centre for Northern Region forTraining and Technical Support, AMC-PGIMER has provided the training topersonals from various medical institutes from North India. AMC-PGIMER is alsoproviding the training to students from Panjab University every year topharmacology students.

Year	ICSRâs Reported (Pharmacovigilance)	Materiovigilance
2010	131 (Oct, Nov, Dec)
2011	1248
2012	1969
2013	2013
2014	3126
2015 -2016	1671	367
2016-2017	1331	367
2017-2018	1482	50
2018-2019	1305	161
2019-2020	161	-0-
2020-2021	1032	246
2021-2022	4690	505
2022-2023	2048	363
2023-2024	4489	1454
2024-2025 (Till Date)	7339	4472

PV/ MV Interns

Materiovigilance

S. No.	Name	Date of Joining	Date of Exit	Time Duration
1.	Lavnaya Batra	3^rd Jan 2024	2^nd April 2024	3 Month
2.	Amisha	2^nd July 2024	1^st Oct 2024	3 Month
3.	Harshita	2^nd July 2024	1^st Oct 2024	3 Month
4.	Akashdeep	5 July 2024	8^th Oct 2024	3 Month
5.	Harwinder	2^nd July 2024	1^st Oct 2024	3 Month
6.	Daksh	2^nd July 2024	1^st Oct 2024	3 Month
7.	Gurjeet kaur	2^nd July 2024	1^st Oct 2024	3 Month
8.	Supriyo khanra	1^st July 2024	4^TH Oct 2024	3 Month
9.	Astha	26 July 2024	26 Oct 2024	3 Month
10.	Kamakshi	1^st Oct 2024	31^st Dec 2024	3 Month
11.	Ayush	1^st Oct 2024	31^st Dec 2024	3 Month
12.	Lavish	10^th jan 2024	9^th April 2024	3 Month
13.	Jasleen	10^th jan 2024	9^th April 2024	3 Month
14.	Kajal	10^th jan 2024	9^th April 2024	3 Month
15.	Traandeep	10^th jan 2024	9^th April 2024	3 Month
16.	Jasmeen	10^th jan 2024	9^th April 2024	3 Month
17.	Tarunpreet kaur	1 st April 2025	30^th Sep 2025	6 Month
18.	Harspreet kaur	1 st April 2025	30^th Sep 2025	6 Month
19.	Pooja	2^nd MAY 2025	2^nd May 2025	3 Month
20.	Kartik Singh	1^st July 2025	30^thSept 2025	3 Month
21.	Tania Rana	7^th July 2025	7^th Oct 2025	3 Month
22.	Parminder kaur	1^st July 2025	1^st Oct 2025	3 Month
23.	Chinmai	17^th July 2025	17^th Jan 2026	6 Month
24.	Rohit singh	17^th July 2025	17^th Oct 2025	3 Month
25.	Sonangki sour	17^th July 2025	17^th Jan 2026	6 Month
26.	Jaanhvi	7^th July 2025	17^th Oct 2025	3 Month
27.	Garima	1^st July 2025	1^st Oct 2025	3 Month
28.	Mritunjay Mishra	06 Oct 2025	06 Jan 2026	3 Month
29.	Tajinder Singh	06 Oct 2025	06 Jan 2026	3 Month
30.	Parneet Kaur	06 Oct 2025	Ongoing	Ongoing
31.	Chehak Chanda	06 Oct 2025	Ongoing	Ongoing
32.	Sakshi	10 Nov 2025	Ongoing	Ongoing
33.	Sachitanand Pattnayak	01 Jan 2026	Ongoing	Ongoing
34.	Nandini Sharma	01 Feb 2026	Ongoing	Ongoing

Pharmacovigilance

S. No.	Name	Date of Joining	Date of Exit	Time Duration
1.	Anushka Vashishth	Jan 2022-	May 2022	4 Months
2.	Arshspreet Kaur	Jan 2022-	May 2022	4 Months
3.	Danish Malhotra	Jan 2022-	May 2022	4 Months
4.	Manasi Varma	Jan 2022-	May 2022	4 Months
5.	Nandita Singh	Jan 2022-	May 2022	4 Months
6.	Prakrita Jyagi	Jan 2022-	May 2022	4 Months
7.	Sharmila Sahoo	Jan 2022-	May 2022	4 Months
8.	Sukhmanpreet Singh	Jan 2022-	May 2022	4 Months
9.	Suryanchal Bhardwaj	Jan 2022-	May 2022	4 Months
10.	Ankit Nagvanshi	Jan 2023	September 2023	9 Months
11.	Karupothula vikil	Jan 2023	September 2023	9 Months
12.	Devika sai katta	Jan 2023	September 2023	9 Months
13.	Smita Suhas Kulkarni	Jan 2023	September 2023	9 Months
14.	Diksha Neharkar	Jan 2023	September 2023	9 Months
15.	Sakshi Awasthi	Jan 2023	September 2023	9 Months
16.	Shweta Patil	Jan 2023	September 2023 September 2023	9 Months
17.	Suraj Singh Thakur	Jan 2023	September 2023	9 Months
18.	Teli Prerana Rajkumar	Jan 2023	September 2023	9 Months
19.	Rashmi Ajaysingh Thakur Tanwar	Jan 2023	September 2023	9 Months
20.	Ajit Yadav	Jan 2023	August 2023	8 Months
21.	Maitry Bhardwaj	Jan 2023	August 2023	8 Months
22.	Nikhita	Jan 2023	August 2023	8 Months
23.	Rubal arora	Jan 2023	August 2023	8 Months
24.	Sakshi	Jan 2023	August 2023	8 Months
25.	Urvashi Atal	Jan 2023	August 2023	8 Months
26.	Yashdeep mukheja	Jan 2023	August 2023	8 Months
27.	Maitry Bhardwaj	15 March 2022	15^th August 2022	6 Months
28.	Abhigyan P Avinashi	1 JULY 2022	13 AUGUST 2022	1 MONTH
29.	Tanay samujh	15 Jan 2023	14 april 2023	3 Months
30.	Davinder Pal Singh	16 Jan 2024	3 rd August 2024	8 Months
31.	Deeksha Thakur	16 Jan 2024	3 rd August 2024	8 Months
32.	Khushbu Keshari	16 Jan 2024	3 rd August 2024	8 Months
33.	Mehak Mangal	16 Jan 2024	3 rd August 2024	8 Months
34.	Mohammad Shafique Ansari	16 Jan 2024	3 rd August 2024	8 Months
35.	Monika Singh	16 Jan 2024	3 rd August 2024	8 Months
36.	Muzamil Qayoom Lone	16 Jan 2024	3 rd August 2024	8 Months
37.	Nitika Chaudhary	16 Jan 2024	3 rd August 2024	8 Months
38.	Nishika Kapoor	16 Jan 2024	3 rd August 2024	8 Months
39.	Srirati Chakraborty	16 Jan 2024	3 rd August 2024	8 Months
40.	Manmeet Kaur	16 Jan 2024	3 rd August 2024	8 Months
41.	Neha Mattoo	16 Jan 2024	3 rd August 2024	8 Months
42.	Vasu Aneja	16 Jan 2024	3 rd August 2024	8 Months
43.	Kashish Pal	5 oct 2024	13 Feb 2024	4 Months
44.	Jatin	16 Jan 2024	30^th June 2024	6 Months
45.	Jatin	16 Jan 2024	30^th June 2024	6 Months
46.	Anjali Saini	1 June 2024	16 Nov 2023	6 Months
47.	Sanjeevani	1 March 2022	25 Aug 2022	6 Months
48.	Mei Nee Chugh	1 March 2022	25 Aug 2022	6 Months
49.	Aditi	1 June 2024	20 Nov. 2024	6 Month
50.	Jasleen	10^th Jan 2025	9^th April 2025	4 Months
51.	Lavish Kaur	10^th Jan 2025	9^th April 2025	4 Months
52.	Taranpreet	10^th Jan 2025	9^th April 2025	4 Months
53.	Jasmeen	10^th Jan 2025	9^th April 2025	4 Months
54.	Kajal preet	10^th Jan 2025	9^th April 2025	4 Months
55.	Vibha Sharma	1 April 2025	20 May 2025	2 Month
56.	Garima	1^st July 2025	30^th September 2025	3 Months
57.	Amisha	15 Jan 2025	2 August 2025	8 Months
58.	Tania	1^st July 2025	30^th September 2025	3 Months
59.	Tarunpreet	1^st April 2025	30^th September 2025	4 Months
60.	Harshpreet	1^st April 2025	30^th September 2025	4 Months
61.	Parminder	1^st July 2025	30^th September 2025	3 Months
62.	Ravi Kant	16^th Jan 2024	30^th April 2025	4 Months
63.	Arayana Sharma	1 May 2025	30th Oct 2025	6 Months
64.	Jayati	1 May 2025	30th Oct 2025	6 Months
65.	Simranjit Kaur	1 May 2025	30th Oct 2025	6 Months
66.	Anjali Thakur	1 May 2025	30th Oct 2025	6 Months
67.	Shiwani Jarial	1 May 2025	30th Oct 2025	6 Months
68.	Navpreet Kaur	1 May 2025	30th Oct 2025	6 Months
69.	Sukhpreet Kaur	1 May 2025	30th Oct 2025	6 Months
70.	Monika Attri	1 May 2025	30th Oct 2025	6 Months
71.	Divya Rehal	1 May 2025	30th Oct 2025	6 Months
72.	Shagun Panjwani	1 May 2025	30th Oct 2025	6 Months
73.	Ananya	1 May 2025	30th Oct 2025	6 Months
74.	Akshita Khawdal	1 May 2025	30th Oct 2025	6 Months
75.	Sudhan Shu	1 May 2025	30th Oct 2025	6 Months
76.	Sahil Vashisht	1 May 2025	30th Oct 2025	6 Months
77.	Mehak Kaur	1 May 2025	30th Oct 2025	6 Months
78.	Aakansha Thakur	1 May 2025	30th Oct 2025	6 Months

And many more since2013.

2024-2025

He conducted several workshops/CMEs as a chairmanof Prof. Bikash Medhi namely 2ndNational Conference on Natural Products (19-21/04/24), CME on PcPI 7 MvPI on28/04/2024, 7th National Workshop on Pharmacogenomics (10-12/05/24), Seminar on"Post-Marketing AE reporting" and Stakeholders' meeting on"Improving Post-Marketing Safety Reporting in MvPI" (03/09/24),Workshop on "In-silico, In-vitro, and IPR in novel medicinal products(04-05/09/24), Symosium on "Medication & Patient Safety"(23/11/24), 3rd National workshop on flowcytometry (01-02/12/24) and 8th NBRL(07-09/02/25).

Achievements inpharmacovigilance (PvPI): PGIMER center for Pharmacovigilance programof India (PvPI) is a Regional Centre for Training and Technical Supportfor North Zone, Dept. of Pharmacology, PGIMER-Chandigarh; the center is workingunder the guidance of Prof. Bikash Medhi (co-ordinator) and Dr. AjayPrakash (Co- Co-coordinator). Total Number of ICSRs was 6677 processed during theyear from PGIMER-Chandigarhto PvPI, NCC-IPC, Ghaziabad, through WHO-UMC Vigiflow Software. Whereas theMvPI managed to report 3002 total medical device adverse events in the currentyear 2023-2024. Prof. Bikash Medhi organized twenty-six differentCME/workshops.

Area Of
Specialization

1. Cognitive Neurosciences
2. Alzheimer, Autism, Epilepsy, Stem Cells, etc.
3. Pharmacogenomics & Pharmacoproteomics
4. PKPD

5. Pharmacovigilance

6. Regulatory Affairs

7. Drug Regulation

Future Plans

1. Multi-Disciplinary Training Program

To build a world-class research environment, the program focuses on the core "Good Practices" and specialized methodologies required for clinical and basic research.

Focus Area	Key Components
Good Clinical Practices (GCP)	Ethical conduct and data integrity in human clinical trials.
Good Laboratory Practices (GLP)	Ensuring reliability and reproducibility in non-clinical safety studies.
Operational Research	Optimizing health systems and improving program delivery.
Medical Ethics	Establishing Institutional Ethics Committees (IECs) and patient safety protocols.
Disease Modeling	Using in-vitro, in-vivo, and computational models to study disease progression

2. IUPHAR & Pharmacology Skill Development

The collaboration with IUPHAR is designed to bridge the gap between basic pharmacology and drug discovery, specifically for those with a pharmacology background.

I. Research Methodology: Training in experimental design, statistical analysis, and the use of the IUPHAR/BPS Guide to PHARMACOLOGY database.
II. Translational Research: Focused skills on moving molecules from the laboratory bench to the patientâs bedside.
III. Regulatory Science: Understanding the pathways for drug approval under the Central Drugs Standard Control Organisation (CDSCO).

3. Integrated Vigilance Framework

A critical part of research capacity is the ability to monitor the safety of medical products once they are in the market. This involves the collection of cases and "Signal Detection" (identifying new risks).

I. Pharmacovigilance (PvPI): Monitoring Adverse Drug Reactions (ADRs) to ensure drug safety.
II. Materiovigilance (MvPI): Monitoring adverse events related to medical devices (coordinated by IPC Ghaziabad).
III. Hemovigilance (HvPI): Monitoring the safety of blood transfusions and blood products.

4. National Programme on AMR Containment

As of 2026, the National Action Plan on AMR (NAP-AMR 2.0) has intensified its focus on a "One Health" approach, linking human, animal, and environmental health.

Core Training Pillars:

I. Antimicrobial Stewardship (AMS): Training clinicians and pharmacologists to ensure the "Right Drug, Right Dose, and Right Duration" to prevent the emergence of "Superbugs."

II. Surveillance Network (NARS-Net): Expanding laboratory capacity to track resistance patterns across 60+ state medical colleges, feeding into the Global Antimicrobial Resistance Surveillance System (GLASS).

III. The "Red Line" Campaign: Educating the public and pharmacists to identify prescription-only antibiotics (marked with a red vertical line) to curb over-the-counter (OTC) misuse.

IV. Environmental Monitoring: Researching antibiotic residue in pharmaceutical industrial effluents and hospital wastewater.

5. Anti-Doping as a Social Responsibility

In the context of Indiaâs growing sporting profile, Anti-Doping is no longer just a regulatory hurdle but a moral and social imperative for the medical community.

The Role of Pharmacology Professionals:

I. Clean Sport Ethics: Moving beyond "detection" to "prevention." Education focuses on the health risks of performance-enhancing drugs (PEDs), such as cardiovascular failure, hormonal imbalance, and mental health issues.

II. Therapeutic Use Exemptions (TUE): Training researchers to help athletes navigate the legal use of necessary medications that might otherwise be on the WADA Prohibited List.

III. Nutritional Supplement Vigilance: Addressing the "Social Responsibility" aspect by testing and certifying supplements to prevent accidental doping due to contaminationâa major issue for budding Indian athletes.

IV. NADA India Collaboration: Aligning with the National Anti-Doping Agency (NADA) to integrate sports pharmacology into the standard pharmacy and medical curriculum.

Awards & Honours

1. Nominated for EWG Group.
2. 25th Lifetime Achievement Award by Amrita Medical College, Kochi.
3. National Award in Mumbai for Cancer Research Foundation.
4. Dr. D N Prasad Memorial Award with Gold medal (ICMR), New Delhi.
5. Dr. V K Bhargava Award with Gold medal (NAMS)
6. Dr. B N. Ghosh Award

7. Rudra Goswami Award

8. Col. Ram Nath Chopra Oration, PK Vaida Oration from Mumbai, Maharashtra, VAIDA AWARD 2023
9. Gujral Bhargava Award on Completion of 100 years.
10. He served as a jury member for the Pharma Award in Delhi, August 28â30 2025
11. Prof. Bikash Medhi has been dedicated to 2% of scientists across the world conducted by Elsevier & Stanford University 2024.
12. Nominated as member executive committee of IUPHAR for Global coverage of IUPHAR activities in coordination with WHO (2023-2026)
13. IUPHAR Chairman for Basic & Translational Science, GCP chairman by Government of India & INSA member for IUPS & IUPHAR
14. Medical Pharmacological Award 2024
15. Prof. Bikash Medhi has been dedicated to 2% of scientists across the world conducted by Elsevier & Stanford University 2023.
16. Col. Ram Nath Chopra Oration, PK kar oration from Indian Pharmacological Society (IPS), VAIDA AWARD 2023
17. Rudra Goswami Oration Award 2023
18. Asia-Specific Award for Forensic Science 2023
19. Prof. Bikash Medhi has been dedicated to 2% of scientists across the world conducted by Elsevier & Stanford University 2022.
20. Awarded Dr. D N Prasad memorial award with Gold medal 2009 from Indian Council of Medical Research (ICMR), New Delhi. (Awarded in 2013)
21. Awarded Dr. V K Bhargava Award with Gold medal from National Academy of Medical Sciences (NAMS) 2013
22. Awarded Dr.B N. Ghosh Oration at 43rd Annual Conference of IPS and International Conference on âPharmacology & Translational Researchâ was organized by National Executive Committee in association with Food and Drug Toxicology Research Centre, National Institute of Nutrition, Hyderabad from 13th â 16th December, 2010.
23. Col. Ram Nath Chopra Oration-December, 2014 in 48th Annual Conference of Indian Pharmacological Society & International Conference in Guwahati, December, 2014.
24. Awarded International Fellowship from Alzheimer's AssociationInternational Organization (AAIC), July 13-18, 2013 at the Boston,USA.
25. Awarded International Fellowship from Alzheimer's AssociationInternational Organization (AAIC), July 18-23, 2015 at the Washigton DC, USA.

26. Awarded from Hasanuddin University, Makassar Indonesia for work on complimentary medicine (honey) September, 2013
27. Best paper award in PGIMER Research Day Symposium 2014.
28. Trained by DST as Good Laboratory Inspector (GLP)2010 under GLP Monitoring Authority, Department of Science and Technology, Government of India.
29. Trained by US-FDA as Good Clinical Inspector (GCP) 2008-2010
30. Investigator Travel award received IN 27thSingapore Congress, July 2007 at Singapore.
31. Awarded MAMS by National Academy of Medical Sciences (India) at KGMC, Lucknow on 31st October 2009
32. Awarded Bharat Joti Award 2013
33. Vikas Ratan Award 2013
34. Awarded a Bursary from Organizer Epilepsy Summer School, VENICE INTERNATIONAL UNIVERSITY, ITALY to participate in 8th international course on Bridging Basic Knowledge with Rational Prescribing in Epileptology, which will be held in San Servolo, Venice, Italy from July 18 to 29, 2010.
35. Awarded Fellowship to assist participation in the 4th Eilat International Educational Course: PHARMACOLOGICAL TREATMENT OF EPILEPSY; Eilat, Israel, September 18-25, 2011 by Jerusalem University
36. Awarded Bursary for Manila Epilepsy Congress 22nd to 25th March 2012
37. Elected as Secretary Clinical Pharmacology, Indian Society of Pharmacology(IPS), India (2012-2014)
38. Co-Chairman India Initiative Programme, Indian Pharmacology Society(IPS) 2014
39. Selected as Core panel of expert for Investigational New Drug committee (IND) under chairmanship of director general & secretary of health, ICMR, Ministry of Health and Family Welfare,Govt of India, Nirman Bhawan, New Delhi.
40. Selected as Core panel of expert for Task Force to frame guidelines for submission of dossiers or proposals for regulation of biotech products (r-D~A product), Ministry of Health and Family Welfare, Govt of India, Nirman Bhawan, New Delhi, 2011
41. Elected for Editorial Board, World Journal of Gastroenterology
42. Elected as Editorial Board for Journal of Neuroscience and Behavioral Health
43. Elected as member advisory board Indian Journal of Pharmacology.
44. Elected for Editorial Board of Gastroenterology and Hepatology (GH).
45. Elected as Editorial Board forJournal of Neuroscience and Behavioral Health.
46. Awarded Best 2nd Prize for paper entitled: âEffects of artemisinin, artemether, arteether on the pharmacokinetics of Phenytoinâ. In International Comprehensive Update on Diagnostic and Therapeutic in Epilepsy and Neuro-Electrophysiology Workshop (CUTE conference), New Delhi, Feb 4-5, 2006.
47. Elected as Fellow of International Medical Sciences Academy(FIMSA) in 2006.
48. Awarded Member of National Medical Academy (MAMS) 2009.
49. Executive Committee Member of Society for Rational Drug Use, India.
50. Travel Grant from Department of Science and Technology (DST) to attend IMSACON at Clare College in July 2002, Cambridge University, UK.
51. Travel Grant from Department of Science and Technology to attend IMSACON at Mayo Clinic in September 2003, Rochester, Minnesota, USA.
52. Travel grant from Indian National Sciences Academy to attend International Challenges in Pediatric Pharmacology, Satellite Symposum (15th World Congress of Pharmacology) Shanghai, China June 28 â 30, 2006.
53. Nominated as Indian delegate to attend IUPHAR, July 2014, Cape town, South Africa from INSA, Govt. of India
54. Travel Award from CSIR 2008 to attend Epilepsy Congress, Berlin, Germany
55. Travel Award from DST 2008 to attend Experimental Biology, Washington DC,USA
56. Travel Award to USA from UGC 2008.
57. Travel Award from UGC 2009, to attend Experimental Biology, New Oreland,USA
58. Travel Award from UGC 2014, to attend Therapeutic Drug Monitoring Conference at Prague, Europe.
59. Executive Committee Member of Society for Rational Drug Use, India.
60. Executive Committee Member of Society for Pharmacovigilance, India.
61. Awarded Bursary to assist participation in the 9th Asian & Oceanian Epilepsy Congress (AOEC), 22-25th March 2012 in Manila, Philippines
62. Awarded Independent Senior Research Fellow (ICMR-SRF) 2012 to Baldeep Kumar under Dr. Bikash Medhi
63. Awarded Independent Senior Research Fellow (ICMR-SRF) 2012 to Rakesh K Ruhela under Dr Bikash Medhi
64. Dr. Bikash Medhi, Dr. Pooja Sarotra and Ajay Prakash awarded for Clinical Research Training program by Department of Biotechnology (DBT) under, MoH, Govt. of India.

65. Kumar B and Medhi B, ICMR awarded to Baldeep Kumar for Clinical Pharmacology training program on PK/PD
66. Ruhela R K and Medhi B, ICMR awarded to Rakesh Kumar Ruhela for Clinical Pharmacology training program on PK/PD
67. Prakash A, Medhi B & Chopra K. ICMR awarded to Ajay Prakash for Clinical Pharmacology training program on PK/PD.
68. Prakash A, Medhi B & Chakrabarty A. Growth factor induced stem cell attenuates an acute phase change induced by partial cerebral ischemia in mice. SfN-IBRO International travel Award, awarded to Ajay Prakash to present their research work in Neuroscience 2012.
69. Mr. Shubham Misra, PhD student has been awarded travel award to attend AAICAD 2011, at Paris France.

70. Awarded Independent Senior Research Fellow (2008) (ICMR-SRF) to Ajay Prakash under Dr. Bikash Medhi
71. Prakash A, Bansal D & Medhi B. DST travel award-2008, granted to Ajay Prakash for presenting their work in Annual meeting of Safety Pharmacology Society, Madison, USA.
72. Awarded International Travel Fellowship from Alzheimer's Association International Organization(AAIC), July 18-22, 2015 at the Washington DC, USA
73. Selected as GLP Inspector by National GLP Compliance Monitoring Authority, Department of Science and Technology (DST), New Delhi

Member Of Professional
Bodies

Positions held in Scientific Societies

1. IUPHAR Chairman for Basic & Translational Science, GCP chairman by Government of India & INSA member for IUPS & IUPHAR
2. Elected as Secretary, Clinical Pharmacology, Indian Society of Pharmacology(IPS), India
3. Co-Chairman India Initiative Programme, Indian Pharmacology Society(IPS)
4. Executive committee member of the Society for Rational Drug Use, India.
5. Executive Committee Member of Society for Pharmacovigilance, India

MEMBER OF NATIONAL SCIENTIFIC BODY/MEMBER OF POLICY MAKING BODY

A. DCGI office Ministry of Health and Family Welfare.

1. Core panel of expert for Investigational New Drug committee (IND) under chairmanship of director general & secretary of health, ICMR, Govt of India, Govt of India, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi.
2. Core panel of expert for Task Force to frame guidelines for submission of dossiers or proposals for regulation of biotech products (r-D~A product),Govt of India, Govt of India, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi, 2011
3. Fixed Dose Committee of DCGI
4. DCGI SAE-Compensation Committee,
5. Essential Medicine committee
6. Subject Expert Committee
7. DGHS panel
8. Sub-committee of Drug Regulation,
9. Schedule Y amendment Committee,
10. Good Clinical Inspector (GCP) for DCGI office
11. Member of Gelatin capsule issue in India

B. Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare

1. Cordinator, Pharmacovigilance Centre &Regional Resource Centre for Northern Region for Training and Technical Support
2. Central Working Group Committee for Pharmacovigilance(PvPI),
3. Member of Signal Preview Committee (PvPI)
4. Core Training Panel Committee Pharmacovigilance (PvPI),
5. National Formulary Committee(NFI)âIPC,
6. Chairman selection Committee for TA(IPC),
7. National Formulary Committee (NFI)

C. National Institute of Biologics, Ministry of Health and Family Welfare.

1. Central Advisory Committee Special invite: Haemovigilance Programme of India (HvPI)
2. Drugs Survey â Core Expert Committee
3. Member of committee for evaluation of Spurious Drugs

D. Indian Council of Medical Research (ICMR), MOHFW,GOI

1. Basic Medical Sciences Project evaluation Committee (ICMR),
2. Antimicrobial Evaluation Committee(ICMR). ,
3. Î²-HCG Vaccine Committee(ICMR),
4. Technical Evaluation Committee of HRD scheme
5. Core member for Committee ICMR-NIREH Bhopal,
6. Member of Advisory Committee meeting to discuss the modalities for setting up a National Centre on Clinical Pharmacology
7. Member of ICMR Technical Committee for procurement of instruments in ICMR HQ/ICMR institute/Centre
8. Member of ICMR funding to CDRI (Under DHR-Reproductive Division)
9. Expert panel memberfor ICMR-academic clinical Research

E. Department of Biotechnology, Ministry of Science and Technology, GOI

1. Task force member of Expert Group on Tuberculosisâ
2. Reviewer for projection evaluation Nutrition devision
3. Member Nano-intiative group-DBT
4. Special Invitee - TB Task Force, DBT Task Force member

F. Department of Science and Technology, MOS,GOI

1. Trained by DST as Good Laboratory Inspector (GLP)2010 under GLP Monitoring Authority, Department of Science and Technology, Government of India.
2. Reviewer for project evaluation-DST
3. Reviewer for project evaluation-DSIR

G. National Anti-doping Agency(NADA), Ministry of Sports, GOI

1. Member of Anti-doping panel
2. Member anti-dpoing awareness programme for NADA.

H. WHO-Country office

1. As expert panel member

I. National Institute of Pharmaceutical and Research (NIPER)

1. Member of senate (academic Council)
2. Member of selection committee
3. Member of IEC-NIPER (Mohali)

J. Punjab University, Chandigarh

1. Member of Board of studies of Punjab University, Chandigarh

K . National Board of Examination

1. Member of expert panel for validation of MCQ
2. Member of Department of Helath Resaerch (DHR), MOH.

List of committees handling by Dr. Bikash Medhi.

Working as Ex- Additional Medical Superintendent Since 7 years

1. Joint Medical Superintendent & Officer Inchage New OPD,Advance Eye centre and Deaddiction Centre (three years )

2. Joint Medical Superintendent and office In charge Advance Cardiac Centre (one year)
3. Joint Medical Superintendent and office In charge Advance Eye Centre till date

4. Others Committee in PGIMER:
5. Replacement of HVAC in New OPD.
Dr. A. Rajwanshi (Chairman) AE (RAC) (convener) Dr. Bikash Medhi (Member)
6. Spot committee
Store Officer (convener) Dr. Bikash Medhi (Chairman)
7. Non purchase committee (furniture/fixture)
Dr . Y.K. Batra (Chairman) Store Officer (Convener) Dr. Bikash Medhi (Member)
8. Non plan purchase committee( Chemicals and Glassware)
Dr. Babu Ram Thapa (Chairman) , Store officer (convener) Dr. Bikash Medhi(member)
9. Irregularities in the Echo Lab appointments
Dr. R.K. Ratho (chairman) Dr. Bikash Medhi (member convener)
10. Safe handling and storage of mercury waste Dr. Bikash Medhi(Chairman)
11. Day care O.T complex New OPD Block
Dr. K.L.N Rao Chairman Dr. Bikash Medhi (member-convener)
12. Inspection committee
Dr. Anil Bhansali (Chairman) Dr. Bikash Medhi (member convener)
13. Udhampur rotary sarai camp (Jammu & Kashmir ) Dr. Bikash Medhi ( Nodal Officer for PGIMER)
14. Computer monitoring committee Member
15. Sanitation tender Member
16. Central committee-Animal House Member
17. Member of Sport Committee, PGIMER, 2005-2006
18. Advisory panel PGIMER Drug Bulletin
19. Member of Advisory Committee Drug Bulletin, PGIMER, Chandigarh
20. Member of Institute Bio safety Committee, PGIMER, 2005-2006

International

1. American Society of Pharmacology and Experimental Therapeutics (ASPET) Regular Member

2. Society of Experimental Biology and Medicine (Regular member)

3. Fellow of International Medical Science Academy (FIMSA)

4. Life member of Scientist of Indian origin in America (Honorary Member

5. International Society of Antimicrobial Society

6. International Union of Physiological Sciences(IUPS)

7. Regular Member of Society of Neurosciences, USA

8. Member of Safety Pharmacology Society (SPS) USA

9. British Pharmacology Society Membership (BPS)

10. Australian Society Clinical and Experimental Pharmacological Society (ASCEPT)

11. European Association for Clinical Pharmacology and Therapeutics(ESCPT)

12. American Society for Clinical Pharmacology and Therapeutics

13. Argentine Society for Experimental Pharmacology

14. Asia Pacific Federation of Pharmacologists

15. Austrian Pharmacological Society.

16. Brazilian Society of Pharmacology and Experimental Therapeutics

17. Canadian Society of Pharmacology and Therapeutics

18. Chinese Pharmacological Society

19. Hong Kong Pharmacology Society

20. European College of Neuro-psychopharmacology

21. Israel Society for Physiology and Pharmacology

22. Japanese Pharmacological Society

23. Latin American Association of Pharmacology

24. South African Society for Basic and Clinical Pharmacology

National (Life member)

Â· Indian Pharmacological Society (IPS)

Â· Association of Physiologists and Pharmacologists of India(APPI)

Â· Indian Society of Anti-Microbial Chemotherapy.

Â· AIIMSONIAN (life member)

Â· Member of Society for Pharmacovigilance India (Life member).

Â· Member of Indian Society for Rational Pharmaco-therapeutics.

Â· Life member of PGIMER Alumni Society

Â· Indian Science Congress

Â· Indian Society of Toxicologists

:: Publications(In Vancouver Style)

Publication

TOTAL - 1100+

(Publications + Book Chapters)

International Journal of Pharmaceutical Sciences and Nanotecnology

Sr. no	Editorial Title	Month of issue
1.	Kumar V, Charan S, Prakash DA, *Medhi Bikash. Phytochemical Nano-Encapsulation with Potential Neuroprotective Efficacy in the Management of Neurodegenerative Disorder .* Scopus Indexed [Internet]. 2025 Dec. 31 [cited 2026 Jan. 22];18(6):8319-25. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/9184	Nov-Dec 2025
2.	Rajaram S, Sharma M, *Medhi Bikash. Organoid and Nanoformulation: A New Dimension in Therapeutics .*** Scopus Indexed [Internet]. 2025 Oct. 15 [cited 2026 Jan. 22];18(5):8225-7. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/8707
3.	Sharma Khushbu and *Medhi Bikash, Designing Nanomedicine based on Gender Differences*, International Journal of Pharmaceutical Sciences and Nanotechnology. 2025, 18(4):8141-8145. MSID: 8466 https://doi.org/10.37285/ijpsn.2025.18.4.1	July â Aug 2025
4.	Sharma M, *Bikash Medhi. Advances in Nanoformulations for Cosmetic Applications*. Scopus Indexed [Internet]. 2025 Jun. 15 [cited 2025 Sep. 22];18(3):8035-9. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/8020	May â June 2025
5.	Garg RI, Masih GD, *Bikash Medhi. Nanoformulation and Fixed Dose Combination.* Scopus Indexed [Internet]. 2025 Apr. 15 [cited 2025 Sep. 22];18(2):7897-901. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/7631	Mar â April 2025
6.	Kumar N, Sharma P, *Bikash Medhi. Critical Appraisal of Guidelines for Nanoparticles in Developed and Developing Countries*. Scopus Indexed [Internet]. 2025 Feb. 15 [cited 2025 Sep. 22];18(1):7749-54. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/7142	Jan-Feb 2025
7.	Gupta S, Kaur H, *Bikash Medhi. Therapeutic Use of Nanoproducts in Clinical Practice and Products in the Pipeline for Clinical Development*. Scopus Indexed [Internet]. 2024 Dec. 15 [cited 2025 Sep. 22];17(6):7651-6. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/6838	Nov-Dec 2024
8.	*Bikash Medhi, Sidana P. Role of Nanotechnology in Combating Ischemic Stroke: Role of Nanotechnology in Combating Ischemic Stroke.* Scopus Indexed [Internet]. 2024 Oct. 15 [cited 2025 Sep. 22];17(5):7561-4. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/6256	Sep-Oct 2024
9.	*Bikash Medhi, Dr. Himanshu Sharma, Dr. Tamanna Kaundal, Dr. Ajay Prakash. Artificial Intelligence: A Catalyst for Breakthroughs in Nanotechnology and Pharmaceutical Research*. Scopus Indexed [Internet]. 2024 Aug. 15 [cited 2025 Sep. 22];17(4):7439-45. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/6039	July-Aug 2024
10.	Nikrita, *Bikash Medhi. Nanosensors: Unveiling the Invisible-Advancement in Drug Detection.* Scopus Indexed [Internet]. 2024 Jun. 30 [cited 2025 Sep. 22];17(3):7327-30. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/5368	May-June 2024
11.	*Bikash Medhi, Charan S, Soloman Singh R, Gladson David Masih, Benjamin Suroy. Nano Revolution: Smart Therapeutics Unleash with Nanomaterials.* Scopus Indexed [Internet]. 2024 Mar. 31 [cited 2025 Sep. 22];17(2):7212-6. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/5030	Mar-April 2024
12.	Gajendra Choudhary, Anushka Ghosh, *Bikash Medhi. Neuroinformatics Unveiled: Information-Based Strategies for Analysing the Multifaceted Aspects of Brain Imaging for CNS Disorders: Neuroinformatics: Unraveling Brain Imaging in CNS Disorders*. Scopus Indexed [Internet]. 2024 Feb. 1 [cited 2025 Sep. 22];17(1):7115-8. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/4924	Jan â Feb 2024
13.	Kaundal T, Prakash DA, *Bikash Medhi. Nano-formulation-based antimicrobial peptides for combating infectious disease.: Nano formulated AMPs for infectious disease.* Scopus Indexed [Internet]. 2023 Nov. 15 [cited 2025 Sep. 22];16(6):7025-9. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/4374	Nov-Dec 2023
14.	Kumari D, *Medhi B. Drug and Gene Delivery Carriers: Biodegradable and Biocompatible.* Scopus Indexed [Internet]. 2023 Sep. 15 [cited 2025 Sep. 22];16(5):6943-4. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/3981	Sep-Oct 2023
15.	*Bikash Medhi*, Gorki V. Application of Nanotechnology in Malaria Research. Scopus Indexed [Internet]. 2023 Jul. 31 [cited 2025 Sep. 22];16(4):6841-3. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/3982	July-Aug 2023
16.	Choudhary G, Dadoo N, Prajapat M, *Medhi B. In-silico Pharmacology for Evidence-Based and Precision Medicine.* Scopus Indexed [Internet]. 2023 Aug. 4 [cited 2025 Sep. 22];16(3):6489-90. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/3740	May-June 2023
17.	*Medhi B, Pattanshetti V. New Trends in Therapy: From Natural Products to Nanomedicine.* Scopus Indexed [Internet]. 2023 May 1 [cited 2025 Sep. 22];16(2):6393-5. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/3573	Mar-April 2023
18.	*Bikash Medhi, Shweta Sinha. Advances in Micro/Nanotechnology in Drug Delivery.* Scopus Indexed [Internet]. 2023 Feb. 13 [cited 2025 Sep. 22];16(1):6263-5. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/3090	Jan-Feb 2023
19.	*Bikash Medhi, J Kumaravel, Prabha PK, Ajay Prakash. Nanomaterials and their Immunological Perspectives.* Scopus Indexed [Internet]. 2022 Dec. 12 [cited 2025 Sep. 22];15(6):6191-5. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/3075	Nov â Dec 2022
20.	*Medhi B, Gupta DS, Prakash DA. Biomimetics & Functional Nanomaterial Imaging: Biomimetics & Functional Nanomaterial Imaging.* Scopus Indexed [Internet]. 2022 Oct. 29 [cited 2025 Sep. 22];15(5):6105-10. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/3001	Sep-Oct 2022
21.	Polymeric Nanocapsules in Drug Delivery	July â Aug 2022
22.	*Medhi B, KAUR S, J DK. Application of Drug Penetration and Drug Delivery systems in fighting against Infectious Disease: Drug Penetration and Drug Delivery systems against Infectious Disease*. Scopus Indexed [Internet]. 2022 Aug. 22 [cited 2025 Sep. 22];15(3):5933-5. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/2895	May-June 2022
23.	*Medhi B, Paras Pahwa. Nanovaccine: Current Status*. Scopus Indexed [Internet]. 2022 May 2 [cited 2025 Sep. 22];15(2):5831-3. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/2655	Mar- April 2022
24.	*Medhi B. Guidelines for Nanopharmaceutical Products for Regulatory Approval* . Scopus Indexed [Internet]. 2022 Feb. 28 [cited 2025 Sep. 22];15(1):5723-5. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/2534	Jan â Feb 2022

DRUG BULLETIN

1. JainM, Prakash A and Medhi B.New Drug Updates: Antihypertensive. Drug Bulletin 2023; 48(1): 01-07.

2. SinghA, Singh RS, Masih GD, Suroy B, Sharma AR, MedhiB. Dietary Supplements. DrugBulletin 2023; 48 (1): 08-21.

3. Nikritaand Medhi B.ComprehensiveStrategies for Poisoning Management: A Current Update. Drug Bulletin2023; 48 (2): 22-28.

4. Gupta S, Prakash A and Medhi B. Management of snakebite.Drug Bulletin 2023; 48 (2): 29-33.

5. Gorki V and MedhiB.New Anti-Malarial Drug Candidates in The Pipeline.Drug Bulletin 2023; 48 (3): 33-39.

6. GeorgeA T. Medhi B.Immunomodulators.Drug Bulletin 2023; 48 (3): 40-55.

7. MeniaN, Mahajan S S. Compliance of Medicines: Drug Bulletin 2023; 48 (4): 56-66.

8. RajP R, Medhi B.AntiparasiticDrugs. Drug Bulletin 2023; 48 (4): 67-73.

9. KumaravelJ, Medhi B.Managementof Poisoning. Drug Bulletin 2022; 47: 1-7.

10. MaheshwariS, Kumar V, Medhi B,Prakash A. Current evidence in the management of cervical spondylosis: a review.Drug Bulletin 2022; 47: 8-15.

11. SharmaN, Prakash A and Medhi B.Therapeutictargets for the prevention of epilepsy. Drug Bulletin 2022; 47 (2):17-28.

12. SuroyB et al.,Current updates in Pharmacovigilance. Drug Bulletin2022; 47 (2): 29-56.

13. SalariaD, Rolta R, Prakash A and Medhi B.Approvalof food products by FSSAI. Drug Bulletin 2022; 47 (3): 57-62.

14. JoshiR, Sharma M, Priyanshi. Drugs Used in Pregnancy and Lactation. Drug Bulletin2022; 47 (3): 63-72.

15. WalterNS, Gorki V and Medhi B.RecentTrends in Drug Development in Parasitic Diseases. Drug Bulletin2022; 47 (4): 73-82.

16. SalariaD, Rolta R, Prakash A and Medhi B.Phytopharmaceuticalsapproved by FSSAI. Drug Bulletin 2022; 47 (3): 84-87.

17. Jain M, Prakash A, MedhiB. Narrow therapeutic index drugs and role of Therapeutic drugmonitoring. Drug Bulletin 2021; 46: 1-5.

18. Thota P, Thota A, Sarma P, Prakash A, Teotia AK,Prakash J, Medhi B. Is itCovid-19 or Dengue fever: what you need to know? Streamlined way ofDifferential diagnosis and management. Drug Bulletin 2021; 46: 6-13.

19. Kaur S, Medhi B. DrugInduced Liver Injury. Drug Bulletin 2021; 46: 14-19.

20. SaifuddinPK, Bhattacharyya A, Sarma P, Mahendiratta S, Kaur H, Chhimba N, Prakash A, Medhi B * , Vaccines for COVID-19.Drug Bulletin 2021; 46 (2): 1-14

21. HandaV, Raja A, Dhibar DP, Medhi B,Currentstatus on the potential Drug Therapies for COVID-19. Drug Bulletin2021; 46(2): 15-30

22. KaurH, Kaur C, Medhi B* , AntibioticResistance. Drug Bulletin 2021; 46 (2): 31-46

23. JainA, Sharma S, Prakash A, Medhi B.Pharmacotherapyfor low backache. Drug Bulletin 2021; 46 (3): 1-6.

24. HandaV, Kumar M, Sharma AR, Medhi B* , AReview on the Potential Toxic Consequences of AlcoholBased Sanitizers.Drug Bulletin 2021; 46 (3): 7-20.

25. SinghA, Singh RS, Masih GD, Suroy B, Sharma AJ, Batra G, Prakash A, Medhi B. Current status of Therapies inInflammatory Bowel Disease. Drug Bulletin 2021; 46 (3): 21-36.

26. PrabhaPK, Choudhary G, Prakash A, Medhi B.Drugapproval in Rare Disease. Drug Bulletin 2021; 46 (4): 1-8.

27. AngraV, Prakash A, Medhi B.Managementof Malaria. Drug Bulletin 2021; 46 (4): 9-21.

28. TondonM, Prakash A, Medhi B.Regulatoryscenario of medical devices in India. Drug Bulletin 2021; 46:22-26.

29. BhattacharjeeS, Medhi B.Managementof Hepatitis C- Current Update. Drug Bulletin 2020; 45: 1-7.

30. MahendruD, Vidya M. Mahalmani, Kumaravel J, Gitika Batra, Prakash A, Medhi B. Recent advances in treatmentof myasthenia gravis. Drug Bulletin 2020; 45: 8-15.

31. SemwalA, Kaur S, Prakash A, Medhi B.DrugTherapy for recent viral epidemic & pandemic. Drug Bulletin2020; 45: 16-22.

32. GoyalPK, Prakash A, Medhi B,Drugaddiction and rehabilitation. Drug Bulletin 2020; 45: 23-30.

33. MahajanE, Medhi B.NewerIron preparations: Comparative efficacy and safety in Iron deficiency anemia.Drug Bulletin 2020; 45:31-35.

34. JainM, Prakash A, Medhi B.Managementof Dyslipidemia. Drug Bulletin 2020; 45: 36-41.

35. SinghA, Yadav M, Kumaravel J, Sharma AR, Mishra A, Prakash A, Medhi B. E-prescription (CPOE) inIndian hospitals: A strategy to prevent prescription errors. DrugBulletin 2020; 45: 42-51.

36. MahajanE, Medhi B.EmpiricalManagement of STDs. Drug Bulletin 2020; 45: 81-83.

37. SharmaM, Sharma AR, Singh A, Saiffuddin PK, Raja A, MedhiB An Overview on surveillance of BiomedicalDevices under Materiovigilance Program of India. Drug Bulletin2020; 45: 84-94.

38. VelK, Ajay P, BikashM. Stem Cell Research: Current Update On Efficacy and Safety.Drug Bulletin 2019; 44(1): 1-6.

39. Devraj,Medhi B.SwineFlu. Drug Bulletin 2019; 44(2): 1-11.

40. SinghA, Singh RS, Sarma P, Kaur H, Mahendiratta S, Batra G, Sharma AJ, Medhi B. Current drug therapies underdevelopment in Celiac disease. Drug Bulletin 2019; 44(3): 1-7.

41. JainA, Prakash A, Medhi B.Orphandrugs. Drug Bulletin 2018; 43(1): 1-6.

42. MahajanE, Medhi B.MemoryEnhancer? Drug Bulletin 2018; 43(2):1-8

43. BoparaiJK, Medhi B,Singh S. Asthma, a chronic inflammatory respiratory disease: An update.Drug bulletin 2018; 43 (3): 1-14.

44. DhirN, Prakash A, Medhi B.Currentupdates in the management of acute ischemic stroke. Drug Bulletin2018; 43(4): 1-6.

45. ThotaP, Thota A, Sarma P, Prakash A, Medhi B.Thestartle reality of medication errors in India: role of pharmacovigilance.Drug Bulletin 2017; 42(1): 1-4.

46. ManavJ, Ajay P, BikashM. Research and development in the management of HIV: Imposition ofNewer drug therapy: Drug Bulletin 2017; 42(2): 1-19

47. KondelR, Pandey AK, Gani Rather II, Medhi B.Hypertensionand adherence. Drug Bulletin 2017; 42(3): 1-12.

48. MishraA, Singla R,Sarma P, Rajput R,Sharma AR, MedhiB. Pharmacotherapy of Autism. Drug Bulletin 2017;42(4): 1-14.

49. MahendruD, Kumar S, Kaur S, Prakash A, Medhi B. Sports medicine team: the backgroundplayers behind a successful athlete. Drug Bulletin 2016; 41(2):1-14.

50. SoniS, Sarma P, Medhi B. Materivigilance: Indianperspective. Drug bulletin 2015: 40(1): 1-15

51. RohilaR, Kumar P, Naveen M, Medhi B.Novelocular drug delivery methods. Drug Bulletin 2015. 40(2): 1-10

52. KrishnamurthyB, Medhi B.MYCOPHENOLATEMOFETIL IN RENAL TRANSPLANT. Drug Bulletin 2015; 40(3): 1-17.

53. SinghS, Chandel S, Bhagat R, Medhi B.Qualityof Medicine. Drug bulletin 2014:39 (1): 1-5

54. RadhikaA, Sarma P, Medhi B.Personalizedtherapy: Current prospects and practical implications. Drugbulletin 2014: 39 (2): 1-9

55. BhagatR, Kumar H, Sarma P, Mishra A, Medhi B.Drugeluting stents. Drug Bulletin 2014: 39 (3): 1-9

56. ReddyDH, Soni H, Chandel S, Medhi B.Poststroke dementia and treatment. Drug Bulletin 2014: 39 (4): 1-8

57. SarmaP, Radhika A, Chakrabarti A, Medhi B.NewerAntiepileptic Drugs. 2013 38(2): 1-45

58. ShyambalajiA, Sarma P, Medhi B,Chakrabarti A. Lifestyle drugs. 2013 38(2): 1-21

59. KrishnamurthyB, Medhi B.GestationalDiabetes Mellitus. 2013 38(3): 1-29

60. BhagatR, Kumar H, Sarma P, Singh S, Chakrabarti A, MedhiB. Orphan Drug and Disease. 201338(4): 1-27

case report

1. Medhi B,Borah C. Diclofenac induced Muscle Necrosis. Journal ofInternational Medical Sciene 2000.

Other Publication

S. No.	PMC ID	Journal Name	Title	Year of Publication	Impact Factor	Citations
1.		Cytokine & Growth Factor Reviews	Dhapola R, Kumari S, Sharma P, Paidlewar M, Vellingiri B, Medhi B, HariKrishnaReddy D. Cytokine associated neuroinflammation in Parkinsonâs Disease: Molecular Pathways, Therapeutic Targets, and Translational Insights. Cytokine & Growth Factor Reviews. 2026 Jan 5.	2026	13	---
2.		Ageing Research Reviews	Kumari S, Dhapola R, Sharma P, Paidlewar M, Vellingiri B, Medhi B, HariKrishnaReddy D. Three-Dimensional Human Brain Organoids: A Next-Generation Model to Decode Alzheimerâs Disease. Ageing Research Reviews. 2025 Oct 24:102928.	2026	13.1
3.		Biochemical Pharmacology	Chaudhary B, Kumari S, Dhapola R, Sharma P, Paidlewar M, Vellingiri B, Medhi B, HariKrishnaReddy D. Calcium dysregulation in Alzheimerâs disease: Unraveling the molecular nexus of neuronal dysfunction and therapeutic opportunities. Biochemical Pharmacology. 2025 Aug 5:117211.	2025	5.8	05
4.		Ageing Research Reviews	Kumari S, Dhapola R, Sharma P, Paidlewar M, Vellingiri B, Medhi B, HariKrishnaReddy D. Unravelling Neuronal Death Mechanisms: The Role of Cytokines and Chemokines in Immune Imbalance in Alzheimerâs Disease Progression. Ageing Research Reviews. 2025 Aug 28:102883.	2025	13.1	05
5.		Discover Medicine	Masih GD, Singh RS, Singh A, Batra G, Suroy B, Choudhary G, Charan S, Bachhal V, Prakash A, Medhi B. Repurposing bicalutamide as a potential inhibitor of MMP13 for osteoarthritis treatment. Discover Medicine. 2025 Dec;2(1):1-6.	2025	1.2	00

Patents

Acetazolamidemicroemulsion topical ophthalmic ocular formulation. New therapeuticsinnovation for glaucoma (Application Number:- 201611032255)

Workshops and Seminars

Organizing Secretary

S.no.	Program	Place	Date
Publication skill development programme
1.	1^st Program	IGIMCH, Patna	23^rd -25^th November, 2018
2.	2^nd Program	Baddi University, Baddi
3.	3^rd Program	Azeezia Medical CollegeKollam	14^th -15^th March,2019
4.	4^th Program	Sikkim Manipal Institute of Medical Sciences, Gangtok	25^th March, 2019
5.	5^th Program	ESIC Medical College, Hyderabad	7^th July, 2019
6.	6^th Program	N. G. Halgekar Institute of Dental Sciences & Central Research Laboratory, Belgaum	3^rd August, 2019
7.	7^th Program	Maharishi Markandeshwar University, Solan	7^th August, 2019
8.	8^th Program	NIB, Greater Noida	3^rd September, 2019
9.	9^th Program	Guru Govind Singh Medical College, Baba Farid University of Health Science, Faridkot	1^st October, 2019
10.	10^th Program	Pt. Jawaharlal Nehru Govt. Medical College & Hospital, Chamba	6^th October, 2019
11.	11^TH Program	Guwahati medical college
12.	12^th program Pharmacology CME 2021 âPublication and Peer reviewâ:	KAHERâs J.N. Medical College, Belagavi	19.03.2021